Metabolic Partnering Terms and Agreements, New Report Launched

The Metabolic Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the metabolic partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter metabolic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors metabolic technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual metabolic deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For more information see - http://mrr.cm/ZQH

The initial chapters of this report provide an orientation of metabolic dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in metabolic dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading metabolic deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of metabolic deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all metabolic deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all metabolic partnering deals signed and announced since 2009. The chapter is organized by specific metabolic therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all metabolic partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in metabolic partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of metabolic technologies and products.

Benefits

Metabolic Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of metabolic deal trends since 2009
• Access metabolic deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between metabolic partner companies
• Comprehensive access to over 1,000 links to actual metabolic deals entered into by the world’s biopharma companies
• Indepth review of metabolic deals entered into by the leading fifty bigpharma companies
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner metabolic opportunities
• Uncover companies actively partnering metabolic opportunities

Spanning over 448 pages, “Metabolic Partnering Terms and Agreements” report covering the Trends in metabolic dealmaking, Leading metabolic deals, Bigpharma metabolic deals, Metabolic partnering contracts directory, Metabolic dealmaking by indication, Partnering resource center, Appendices.

For more information see - http://mrr.cm/ZQH